Advanced Biomed Inc. (NASDAQ:ADVB) Stock Short Interest Rises 91.9%

Posted by James Conley on Oct 14th, 2026

Advanced Biomed Inc. (NASDAQ:ADVB – Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 18,897 shares, a growth of 91.9% from the September 15th total of 9,845 shares. Approximately 1.6% of the company’s stock are short sold. Based on an average daily volume of 22,487 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ADVB shares. Wall Street Zen raised Advanced Biomed to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings lowered Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Advanced Biomed presently has an average rating of “Sell”.

Get Our Latest Analysis on ADVB

Advanced Biomed Stock Down 2.3%

NASDAQ ADVB opened at $5.16 on Wednesday. Advanced Biomed has a 52 week low of $3.61 and a 52 week high of $24.23. The company has a 50 day moving average price of $7.70 and a 200 day moving average price of $6.46. The firm has a market cap of $8.51 million, a PE ratio of 1.05 and a beta of 0.01.

Advanced Biomed (NASDAQ:ADVB – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $0.44 earnings per share for the quarter.

Advanced Biomed Company Profile

(Get Free Report)

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.